EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Divergent ERα co-factor landscapes in gynecological cancers: implications for disease progression and therapy

Jenna Grindeland, Jasper Yang, Jerome Yang, Motoki Takaku, Archana Dhasarathy iD

Biochemistry and Cell Biology · 2025

DOI: 10.1139/bcb-2025-0158 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemistry and Cell Biology, 2025. Verfasst von Jenna Grindeland und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND, USA. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Hepatocyte Nuclear Factor 3-alpha, GATA3 Transcription Factor, Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Office of Experimental Program to Stimulate Competitive Research, American Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Estrogen receptor alpha (ERα) is an established biomarker for breast tumors, the loss of which is associated with poor cancer progression. Over 70% of breast cancers express ERα and targeting this protein has helped stem the progress of breast cancer. Therefore, it is paradoxical that only a small fraction of patients with ovarian and uterine cancers, which express ERα, are insensitive to antiestrogenic therapies. We propose the hypothesis that ERα association with different cofactors dictates the susceptibility of these cancers to therapies. To support this hypothesis, we analyzed data from cBioportal patient samples and showed that a strong positive correlation exists between ERα and its cofactors GATA3 and FOXA1 in breast cancer, but not in ovarian and uterine cancers. We further show that ERα genomic localization differs in the three cancer types, using available ChIP-seq datasets. Together, our analyses suggest that both localization and the nature of co-factors might be relevant for driving ERα-dependent cancer progression in different cell environments. We further discuss potential mechanisms for these differences in this commentary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Estrogen Receptor alphaHepatocyte Nuclear Factor 3-alphaGATA3 Transcription FactorBreast NeoplasmsGenital Neoplasms, FemaleHumansFemaleDisease ProgressionGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

GATA3breast cancerendometrial cancerestrogen receptor alphaovarian cancerpioneer factors

Substanzen

Estrogen Receptor alphaESR1 protein, humanHepatocyte Nuclear Factor 3-alphaFOXA1 protein, humanGATA3 Transcription FactorGATA3 protein, human

Autor:innen und Institutionen

  • University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND, USA.
  • Carleton College, Northfield, MN, USA.
  • Northwestern University, Evanston, IL, USA.

ORCID-Profile: Archana Dhasarathy

Förderung

  • NIGMS NIH HHS
  • Office of Experimental Program to Stimulate Competitive Research
  • American Cancer Society
  • National Institute of General Medical Sciences

Zitieren

APA

Grindeland, J., Yang, J., Yang, J., Takaku, M., & Dhasarathy, A. (2025). Divergent ERα co-factor landscapes in gynecological cancers: implications for disease progression and therapy. Biochemistry and Cell Biology. https://doi.org/10.1139/bcb-2025-0158

Vancouver

Grindeland J, Yang J, Yang J, Takaku M, Dhasarathy A. Divergent ERα co-factor landscapes in gynecological cancers: implications for disease progression and therapy. Biochemistry and Cell Biology. 2025. doi:10.1139/bcb-2025-0158

BibTeX
@article{Grindeland2025,
  author = {Grindeland, Jenna and Yang, Jasper and Yang, Jerome and Takaku, Motoki and Dhasarathy, Archana},
  title = {Divergent ERα co-factor landscapes in gynecological cancers: implications for disease progression and therapy},
  journal = {Biochemistry and Cell Biology},
  year = {2025},
  doi = {10.1139/bcb-2025-0158}
}
Kostenlos starten →